BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 16221226)

  • 1. Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine.
    Briguori C; Colombo A; Airoldi F; Morici N; Sangiorgi GM; Violante A; Focaccio A; Montorfano M; Carlino M; Condorelli G; Ricciardelli B
    Kidney Int; 2005 Nov; 68(5):2250-5. PubMed ID: 16221226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC)].
    Vallero A; Cesano G; Pozzato M; Garbo R; Minelli M; Quarello F; Formica M
    G Ital Nefrol; 2002; 19(5):529-33. PubMed ID: 12439841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity.
    Briguori C; Colombo A; Violante A; Balestrieri P; Manganelli F; Paolo Elia P; Golia B; Lepore S; Riviezzo G; Scarpato P; Focaccio A; Librera M; Bonizzoni E; Ricciardelli B
    Eur Heart J; 2004 Feb; 25(3):206-11. PubMed ID: 14972420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iso-osmolality versus low-osmolality iodinated contrast medium at intravenous contrast-enhanced CT: effect on kidney function.
    Nguyen SA; Suranyi P; Ravenel JG; Randall PK; Romano PB; Strom KA; Costello P; Schoepf UJ
    Radiology; 2008 Jul; 248(1):97-105. PubMed ID: 18483232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies.
    Briguori C; Airoldi F; D'Andrea D; Bonizzoni E; Morici N; Focaccio A; Michev I; Montorfano M; Carlino M; Cosgrave J; Ricciardelli B; Colombo A
    Circulation; 2007 Mar; 115(10):1211-7. PubMed ID: 17309916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] Trial).
    Bolognese L; Falsini G; Schwenke C; Grotti S; Limbruno U; Liistro F; Carrera A; Angioli P; Picchi A; Ducci K; Pierli C
    Am J Cardiol; 2012 Jan; 109(1):67-74. PubMed ID: 21943940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The contrast media and nephrotoxicity following coronary revascularization by primary angioplasty for acute myocardial infarction study: design and rationale of the CONTRAST-AMI study.
    Bolognese L; Falsini G; Grotti S; Limbruno U; Liistro F; Carrera A; Angioli P; Picchi A; Ducci K; Pierli C
    J Cardiovasc Med (Hagerstown); 2010 Mar; 11(3):199-206. PubMed ID: 19829124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity.
    Briguori C; Colombo A; Airoldi F; Violante A; Castelli A; Balestrieri P; Paolo Elia P; Golia B; Lepore S; Riviezzo G; Scarpato P; Librera M; Focaccio A; Ricciardelli B
    J Am Coll Cardiol; 2004 Aug; 44(4):762-5. PubMed ID: 15312855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal insufficiency following contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design.
    Briguori C; Visconti G; Ricciardelli B; Condorelli G;
    EuroIntervention; 2011 Apr; 6(9):1117-22, 7. PubMed ID: 21518686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures.
    Briguori C; Colombo A; Airoldi F; Melzi G; Michev I; Carlino M; Montorfano M; Chieffo A; Bellanca R; Ricciardelli B
    Catheter Cardiovasc Interv; 2006 Feb; 67(2):175-80. PubMed ID: 16400668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention: a randomized trial.
    Juergens CP; Winter JP; Nguyen-Do P; Lo S; French JK; Hallani H; Fernandes C; Jepson N; Leung DY
    Intern Med J; 2009 Jan; 39(1):25-31. PubMed ID: 18771430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The osmolality of nonionic, iodinated contrast agents as an important factor for renal safety.
    Lenhard DC; Pietsch H; Sieber MA; Ernst R; Lengsfeld P; Ellinghaus P; Jost G
    Invest Radiol; 2012 Sep; 47(9):503-10. PubMed ID: 22864374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contrast-induced acute kidney injury in patients with renal dysfunction undergoing a coronary procedure and receiving non-ionic low-osmolar versus iso-osmolar contrast media.
    Alexopoulos E; Spargias K; Kyrzopoulos S; Manginas A; Pavlides G; Voudris V; Lerakis S; McLean DS; Cokkinos DV
    Am J Med Sci; 2010 Jan; 339(1):25-30. PubMed ID: 19996728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iso-osmolar radio contrast iodixanol in patients with chronic kidney disease.
    Tadros GM; Malik JA; Manske CL; Kasiske BL; Dickinson SE; Herzog CA; Wilson RF; Das G; Panetta CJ
    J Invasive Cardiol; 2005 Apr; 17(4):211-5. PubMed ID: 15831975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of contrast-induced nephrotoxicity of iodixanol and iopromide in patients with renal insufficiency undergoing coronary angiography.
    Shin DH; Choi DJ; Youn TJ; Yoon CH; Suh JW; Kim KI; Cho YS; Cho GY; Chae IH; Kim CH
    Am J Cardiol; 2011 Jul; 108(2):189-94. PubMed ID: 21545991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of iso- versus low-osmolality contrast media in outpatients with high risk of contrast medium-induced nephropathy.
    Chicaíza-Becerra LA; García-Molina M; Gamboa Ó
    Biomedica; 2012 Jun; 32(2):182-8. PubMed ID: 23242291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study.
    Mehran R; Nikolsky E; Kirtane AJ; Caixeta A; Wong SC; Teirstein PS; Downey WE; Batchelor WB; Casterella PJ; Kim YH; Fahy M; Dangas GD
    JACC Cardiovasc Interv; 2009 May; 2(5):415-21. PubMed ID: 19463464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patients.
    Feldkamp T; Baumgart D; Elsner M; Herget-Rosenthal S; Pietruck F; Erbel R; Philipp T; Kribben A
    Clin Nephrol; 2006 Nov; 66(5):322-30. PubMed ID: 17140161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials.
    Heinrich MC; Häberle L; Müller V; Bautz W; Uder M
    Radiology; 2009 Jan; 250(1):68-86. PubMed ID: 19092091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrotoxic effects in high-risk patients undergoing angiography.
    Aspelin P; Aubry P; Fransson SG; Strasser R; Willenbrock R; Berg KJ;
    N Engl J Med; 2003 Feb; 348(6):491-9. PubMed ID: 12571256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.